5VT0 Stock Overview
A clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
vTv Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.70 |
| 52 Week High | US$27.00 |
| 52 Week Low | US$11.12 |
| Beta | 0.59 |
| 11 Month Change | -27.31% |
| 3 Month Change | n/a |
| 1 Year Change | -41.42% |
| 33 Year Change | -78.61% |
| 5 Year Change | -67.56% |
| Change since IPO | -95.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5VT0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.2% | -3.0% | -0.1% |
| 1Y | -41.4% | -19.4% | 2.3% |
Return vs Industry: 5VT0 underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 5VT0 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 5VT0 volatility | |
|---|---|
| 5VT0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5VT0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 5VT0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 16 | Paul Sekhri | vtvtherapeutics.com |
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company’s lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention.
vTv Therapeutics Inc. Fundamentals Summary
| 5VT0 fundamental statistics | |
|---|---|
| Market cap | €49.46m |
| Earnings (TTM) | -€19.18m |
| Revenue (TTM) | €930.40k |
43.0x
P/S Ratio-2.1x
P/E RatioIs 5VT0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5VT0 income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | US$12.30m |
| Gross Profit | -US$11.30m |
| Other Expenses | US$9.31m |
| Earnings | -US$20.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.47 |
| Gross Margin | -1,130.20% |
| Net Profit Margin | -2,061.60% |
| Debt/Equity Ratio | 0% |
How did 5VT0 perform over the long term?
See historical performance and comparison